Seres Therapeutics
MCRB
60 hedge funds and large institutions have $409M invested in Seres Therapeutics in 2015 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 16 closing their positions.
158,200% more call options, than puts
Call options by funds: $1.58M | Put options by funds: $1K
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
33% more funds holding
Funds holding: 45 → 60 (+15)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $471M → $409M (-$62.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.7M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$23.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.8M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$8.35M |
| 5 |
BM
Bridger Management
New York
|
+$8.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$12.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.02M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$3.57M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$2.58M |
| 5 |
PA
Perceptive Advisors
New York
|
-$2.08M |
MCRB Hedge Fund Activity: Q3 2015 in Review
60 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2015, worth a combined $409M — down 13% from $471M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new MCRB positions and 16 closed out — a net gain of 15 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $24.7M. The largest seller was BlackRock Advisors, cutting an estimated $12.6M.
- 60 institutional investors held Seres Therapeutics (MCRB) as of Q3 2015, up from 45 in Q2 2015.
- Funds reported $409M of Seres Therapeutics stock for Q3 2015, down 13% quarter-over-quarter.
- 31 funds opened new Seres Therapeutics positions in Q3 2015 and 16 closed out, a net change of +15 holders.
- The largest Seres Therapeutics buyer in Q3 2015 was Fidelity Investments, an estimated $24.7M added.
- The largest Seres Therapeutics seller in Q3 2015 was BlackRock Advisors, an estimated $12.6M sold.
Based on aggregated 13F filings for Q3 2015.